A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...
Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases
Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.
200 mg of caffeine elevated the blood pressure after 2 hours but did not impact the retinal VD.
In this final episode, DMEI’s residents share their future plans for expanding the device capabilities and offer practical ...
Victoria Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency ...
Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback